These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption. Klingel R; Heibges A; Fassbender C Atheroscler Suppl; 2013 Jan; 14(1):161-5. PubMed ID: 23357159 [TBL] [Abstract][Full Text] [Related]
28. Feasibility of pediatric plasma apheresis in intensive care settings. Haque A; Sher G; Hoda M; Moiz B Ther Apher Dial; 2014 Oct; 18(5):497-501. PubMed ID: 24674133 [TBL] [Abstract][Full Text] [Related]
29. The effect of immunoadsorption with the Immusorba TR-350 column on coagulation compared to plasma exchange. Koessler J; Kobsar A; Kuhn S; Koessler A; Yilmaz P; Weinig E; Putz E; Boeck M; Klinker E Vox Sang; 2015 Jan; 108(1):46-51. PubMed ID: 25131310 [TBL] [Abstract][Full Text] [Related]
32. Plasma exchange for the patients with dilated cardiomyopathy in children is safe and effective in improving both cardiac function and daily activities. Moriguchi T; Koizumi K; Matsuda K; Harii N; Goto J; Harada D; Sugawara H; Hoshiai M; Kise H; Baba A J Artif Organs; 2017 Sep; 20(3):236-243. PubMed ID: 28382424 [TBL] [Abstract][Full Text] [Related]
33. Comparing the efficacy of three techniques to reduce isoagglutinin titers in AB0 incompatible kidney transplant recipients. Parmentier SP; Rosenkranz E; Schirutschke H; Opgenoorth M; Quick C; Hoelig K; Rosner A; Hohenstein B; Hugo C; Passauer J Atheroscler Suppl; 2017 Nov; 30():253-256. PubMed ID: 29096846 [TBL] [Abstract][Full Text] [Related]
34. Frequency of immediate adverse effects associated with therapeutic apheresis. McLeod BC; Sniecinski I; Ciavarella D; Owen H; Price TH; Randels MJ; Smith JW Transfusion; 1999 Mar; 39(3):282-8. PubMed ID: 10204591 [TBL] [Abstract][Full Text] [Related]
35. Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis. Stork L; Ellenberger D; Beißbarth T; Friede T; Lucchinetti CF; Brück W; Metz I JAMA Neurol; 2018 Apr; 75(4):428-435. PubMed ID: 29404583 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic apheresis in neurological disorders: a survey of the evidence in support of current category I and II indications for therapeutic plasma exchange. Weinstein R J Clin Apher; 2008; 23(6):196-201. PubMed ID: 18973115 [TBL] [Abstract][Full Text] [Related]
38. Scope and application of therapeutic apheresis: Experience from a tertiary care hospital in North India. Sharma RR; Saluja K; Jain A; Dhawan HK; Thakral B; Marwaha N Transfus Apher Sci; 2011 Dec; 45(3):239-45. PubMed ID: 22036963 [TBL] [Abstract][Full Text] [Related]
39. Plasma exchange or immunoadsorption in patients with rapidly progressive crescentic glomerulonephritis. A Swedish multi-center study. Stegmayr BG; Almroth G; Berlin G; Fehrman I; Kurkus J; Norda R; Olander R; Sterner G; Thysell H; Wikström B; Wirén JE Int J Artif Organs; 1999 Feb; 22(2):81-7. PubMed ID: 10212042 [TBL] [Abstract][Full Text] [Related]
40. Actual situation of lipoprotein apheresis in Saxony in 2013. Emmrich U; Hohenstein B; Julius U Atheroscler Suppl; 2015 May; 18():215-25. PubMed ID: 25936329 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]